Testing the pathway in disease models

1:22:53>> progress. Yeah. >> Of high altitude Tibetan animals and how they survive hypoxia which are low oxygen environments. They're able to survive because in low oxygen environments you see the same depletion of your myelin sheath that you do similarly in MS. And so whatever the active ingredient to their solution for the hypoxia problem, our intuition was like other evolutionary, you know, solutions. The Gila monster venom to >> it's doing something. >> Perhaps we can translate this into uh a biologic solution for humans. We've now gotten to the point where we've found the selective targeting of RXR gamma through uh uh AD uh

1:23:33>> ATDR ATDR/ AD and there's some pros and cons to both. >> Yeah. >> But like we know how to target so that the neurons signals to the OPC's to mature to restart this process of creating the mileage. >> Exactly. And the ATDR we can just put in because the neurons can take that and create >> the thing they need to do. >> The thing they need to do, right? We don't need to give the OPC's the the signal in itself. We can just have the neurons >> do it. Which is actually an important distinction. Yeah. That's >> because the ATDR is a bit easier to make. >> Right. Right. That's an important point. Okay. Yes.